Vivacelle Bio, a leading biopharma company, is making waves in the field of shock and trauma treatment with its robust pipeline of therapies. Spearheaded by VBI-S, a Phase 3-ready asset focused on hypotension and hypovolemia in septic shock patients, and VBI-1, a Phase 2-ready candidate for hemorrhagic shock, the company is at the forefront of innovative medical solutions.
Recently, Vivacelle Bio’s President and Chief Innovation Officer, Dr. Cuthbert Simpkins, has been invited by the National Institutes of Health (NIH) to present data on the company’s late-stage clinical programs at the 2024 BIO International Convention. This prestigious event will showcase Vivacelle’s groundbreaking phospholipid nanoparticle technology, which has shown remarkable results in treating critical conditions like hypovolemic septic shock.
CEO, Dr. Harrow DeShield, expressed excitement about the progress made by Vivacelle, highlighting the 100% efficacy results from the VBI-S Phase 2 trial and the publication of a groundbreaking study in The Lancet eClinicalMedicine. These achievements have positioned the company for discussions with potential partners, investors, and commercial collaborators at BIO.
The innovative phospholipid nanoparticle technology utilized by Vivacelle Bio has the potential to revolutionize the treatment of septic shock, a condition that affects millions worldwide. With a focus on elevating blood pressure and reversing organ failure, VBI-S has shown to be both safe and effective, garnering support from the US Department of Defense and the NIH.
Funding for Vivacelle’s Phase 2a clinical trial and upcoming Phase 3 study of VBI-S is provided by the Naval Medical Research Command (NMRC) – Naval Advanced Medical Development (NAMD) program through the Medical Technology Enterprise Consortium (MTEC). This collaboration underscores the critical importance of Vivacelle’s work in advancing medical solutions for those in need.
Vivacelle Bio’s commitment to innovation and excellence in the field of shock and trauma treatments is evident in its groundbreaking research and clinical achievements. With a focus on saving lives and improving patient outcomes, the company’s pioneering approach is set to make a significant impact in the healthcare industry.
For more information about Vivacelle Bio and its groundbreaking therapies, visit their website at https://www.vivacellebio.com. Join us in supporting their mission to revolutionize shock and trauma treatment for the betterment of individuals worldwide.
Source link
